Decreased expression of osteopantin is related to tumor aggressiveness and clinical outcome of intrahepatic cholangiocarcinoma

Liver International

Volumn 24, Issue 1, 2004, Pages 38-45

  Terashi, Takahiro ^a   Aishima, Shinichi ^a   Taguchi, Kenichi ^a   Asayama, Yoshiki ^a   Sugimachi, Keishi ^a   Matsuura, Shuji ^a   Shimada, Mitsuo ^a   Maehara, Shinichiro ^a   Maehara, Yoshihiko ^a   Tsuneyoshi, Masazumi ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Aggressiveness; Carcinoma; Clinical outcome; Immunohistochemistry; Intrahepatic cholangio; Invasion; Metastasis; Osteopontin

Indexed keywords

MESSENGER RNA; OSTEOPONTIN; SIALOGLYCOPROTEIN; SPP1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER INVASION; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CARCINOGENESIS; LIVER METASTASIS; LYMPH NODE METASTASIS; LYMPHATIC SYSTEM; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PERINEURIUM; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE; BILE DUCT TUMOR; BIOSYNTHESIS; CELL ADHESION; INTRAHEPATIC BILE DUCT; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; SURVIVAL;

ADULT; AGED; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CELL ADHESION; CHOLANGIOCARCINOMA; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; OSTEOPONTIN; SIALOGLYCOPROTEINS; SURVIVAL ANALYSIS;

EID: 12144291339     PISSN: 14783223     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2004.00886.x     Document Type: Article

References (42)

1. Ake O, Ahnders F, Dick H. Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Biochemistry-US 1986; 83: 8819-23.
2. Adam J O, Roger B, Philip S R. The role of osteopontin in tumorigenesis and metastasis. Invas Metast 1997; 17: 1-15.
3. David T D, Cecilia M G, Susan R R. Role of osteopontin in cellular signaling and toxicant injury. Annu Rev Pharmacol 2001; 41: 723-49.
4. Weber G F. The metastasis gene osteopontin: a candidate target for cancer therapy. BBA 2001; 1552: 61-85.
5. Gotoh M, Sakamoto M, Kanetaka K, Chuuma M, Hirohashi S. Overexpression of osteopontin in hepatocellular carcinoma. Pathol Int 2002; 52: 19-24.
6. Lawrence F B, Ageliki P S, Brygida B, Eleanor J M, Kathi T, Carole A P, Harold F D, et al. Osteopontin expression and distribution in human carcinomas. Am J Pathol 1994; 145: 610-23.
7. Tuck A B, O'Malley F P, Singhal H, Harris J F, Tonkin K S, Kerkvliet N, Sasd Z, et al. Osteopontin expression in a group of lymph node negative breast cancer patients. Int J Cancer (Pred Oncol) 1998; 79: 502-8.
8. Singhal H, Bautista D S, Tonkin K S, O'Malley F P, Tuck A B, Chambers A F, Harris J F. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res 1997; 3: 605-11.
9. Angelucci A, Festuccia C, D'Andrea G, Teti A, Bologna M. Osteopontin modulates prostate carcinoma invasive capacity through RGD-dependent upregulation of plasminogen activators. Biol Chem 2002; 383: 229-34.
10. Ue T, Yokozaki H, Kitadai Y, Yamamoto S, Yasui W, Ishikawa T, Tahara E. Co-expression of osteopontin and CD44v9 in gastric cancer. Int J Cancer (Pred Oncol) 1998; 79: 127-32.
11. Casson A G, Wilson S M, McCart J A, O'Malley F P, Ozcelik H, Tsao M S, Chambers A F. Ras mutation and expression of the ras-regulated genes osteopontin and cathepsin L in human esophageal cancer. Int J Cancer 1997; 72: 739-45.
12. Shijubo N, Uede T, Kon S, Maede M, Segawa T, Imada A, Hirasawa M, et al. Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma. Am J Resp Crit Care Med 1999; 160: 1269-73.
13. Kim Y W, Park Y K, Lee J, Ko S W, Yang M H. Expression of osteopontin and osteonectin in breast cancer. J Korean Med Sci 1998; 13: 652-7.
14. Kawarada Y, Mizumoto R. Diagnosis and treatment of cholangiocellular carcinoma of the liver. Hepato-Gastroenterol 1990; 37: 170-81.
15. Chou F F, Sheen-Chen S M, Chen C L, Chen Y S, Chen M C. Prognostic factors of resectable intrahepatic cholangiocarcinoma. J Surg Oncol 1995; 59: 40-4.
16. Liver Cancer Study Group of Japan. Primary liver cancer in Japan. Clinicopathologic features and results of surgical treatment. Ann Surg 1990; 211: 277-87.
17. Kosuge T, Yamamoto J, Shimada K, Yamasaki S, Makuuchi M. Improved surgical results for hilar cholangiocarcinoma with procedures including major hepatic resection. Ann Surg 1999; 230: 663-71.
18. Inoue K, Makuuchi M, Takayama T, Torzilli G, Yamamoto J, Shimada K, Kosuge T, et al. Long-term survival and prognostic factors in the surgical treatment of mass-forming type cholangiocarcinoma. Surgery 2000; 127: 498-505.
19. Uenishi T, Hirohashi K, Kubo S, Yamamoto T, Yamazaki O, Kinoshita H. Clinicopathological factors predicting outcome after resection of mass-forming intrahepatic cholangiocarcinoma. Brit J Surg 2001; 88: 969-74.
20. Kajiyama K, Maeda T, Takenaka K, Sugimachi K, Tsuneyoshi M. The significance of stromal desmoplasia in intrahepatic cholangiocarcinoma. Am J Surg Pathol 1999; 23: 892-902.
21. Taguchi K, Aishima S, Asayama Y, Kajiyama K, Kinukawa N, Shimada M, Sugimachi K, et al. The role of p27kip1 protein expression on the biological behavior of intrahepatic cholangiocarcinoma. Hepatology 2001; 33: 1118-23.
22. Sakamoto A, Oda Y, Iwamoto Y, Tsuneyoshi M. A comparative study of fibrous dysplasia and osteofibrous dysplasia with regard to expression of c-fos and c-jun products and bone matrix proteins: a clinicopathologic review and immunohistochemical study of c-fos, c-jun, type I collagen, osteopontin, osteonectin, and osteocalcin. Hum Pathol 1999; 30: 1418-26.
23. Zhang J, Takahashi K, Takahashi F, Shimizu K, Ohshita F, Kameda Y, Maeda K, et al. Differential osteopontin expression in lung cancer. Cancer Lett 2001; 171: 215-22.
24. Sodek J, Ganss T, Mckee M D. Osteopontin. Crit Rev Oral Biol M 2000; 11: 279-303.
25. Mori M, Mimori K, Inoue H, Barnard G F, Tsuji K, Nanbara S, Ueo H, et al. Detection of cancer micro-metastases in lymphnodes by reverse transcriptase-polymerase chain reaction. Cancer Res 1995; 55: 3417-20.
26. Utsunomiya T, Hara Y, Kataoka A, Morita M, Arakawa H, Mori M, Nishimura S. Cystatin-like metastasis-associated protein mRNA expression in human colorectal cancer is associated with both liver metastasis and patient survival. Clin Cancer Res 2002; 8: 2591-94.
27. Oki E, Maehara Y, Tokunaga E, Shibahara K, Hasuda S, Kakeji Y, Sugimachi K. Detection of disseminated cancer cells in bone marrow of gastric cancer using real time quantitative reverse transcriptase polymerase chain reaction. Cancer Lett 2002; 188: 191-8.
28. Fujiwara H, Terashima M, Irinoda T, Takanaga A, Abe K, Kashiwaba M, Oyama K, et al. Quantitative measurement of thymidylate synthase and dihydropyrimidine dehydrogenase mRNA level in gastric cancer by realtime RT-PCR. Jpn J Cancer Res 2002; 93: 1342-50.
29. Sugimachi K, Aishima S, Taguchi K, Tanaka S, Shimada M, Kajiyama K, Sugimachi K, et al. The role of overexpression and gene amplification of cyclin D1 in intrahepatic cholangiocarcinoma. J Hepatol 2001; 35: 74-9.
30. Aishima S, Taguchi K, Sugimachi K, Shimada M, Sugimachi K, Tsuneyoshi M. c-erbB-2 and c-Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma. Histopathology 2002; 40: 269-78.
31. Sung V, Gilles C, Murray A, Clarke R, Aaron A D, Azumi N, Thompson E W. The LCC15-MB human breast cancer cell line expression osteopontin and exhibits an invasive and metastatic phenotype. Exp Cell Res 1998; 241: 273-84.
32. Subha P, Anuradha B, Gopal K. Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-κB-mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells. J Biol Chem 2001; 276: 44926-35.
33. Helluin O, Chan C, Vilaire G, Mousa S, Degrado W F, Bennett J S. The activation state of v3 regulates platelet and lymphocyte adhesion to intact and thrombin-cleaved osteopontin. J Biol Chem 2000; 275: 18337-43.
34. Weber G F, Ashkar S, Glimcher M J, Cantor H. Receptor-ligand interaction between CD44 and osteopontin (ETA-1). Science 1996; 271: 509-12.
35. Beviclaqua G, Sobel M E, Lance A, Liotta L A, Steeg P S. Association of low nm23-H1 RNA levels in human primary breast carcinoma with lymph node involvement and other histopathological indicators of high metastatic potential. Cancer Res 1989; 49: 185-90.
36. Shimada M, Taguchi K, Hasegawa H, Gion T, Shirabe K, Tsuneyoshi M, Sugimachi K. Nm23-H1 expression in intrahepatic or extrahepatic metastasis of hepatocellular carcinoma. Liver 1998; 18: 337-42.
37. Maass N, Hojo T, Ueding M, Luttges J, Kloppel G, Jonat W, Nagasaki K. Expression of the tumor suppressor gene Maspin in human pancreatic cancers. Clin Cancer Res 2001; 7: 812-7.
38. Ashkar S, Weber G F, Panoutsakopulou V, Sanchirico M E, Jansson M, Zawaideh S, Rittling S R, et al. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 2000; 287: 860-4.
39. Cui J, Shin T, Kawano T, Sato H, Kondo E, Toura I, Kaneko Y, et al. Requirement for Valpha 14 NKT cells in IL-12-mediated rejection of tumors. Science 1999; 278: 1623-6.
40. Rodolfo M, Colombo M P. Interleukin-12 as an adjuvant for cancer immunotherapy. Methods 1999; 19: 114-20.
41. Crawford H C, Matrisian L M, Liaw L. Distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression in vivo. Cancer Res 1998; 58: 5206-15.
42. Kawashima R, Mochida S, Matsui A, Youlutuz Y, Ishikawa K, Toshima K, Yamanobe F, et al. Expression of osteopontin in Kupffer cells and hepatic macrophages and stellate cells in rat liver after carbon tetrachloride intoxication: a possible factor for macrophage migration into hepatic necrotic areas. Biochem Biophys Res Commun 1999; 256: 527-31.